03:28

Brian's Story | Prospera Kidney

21:55

How Dr. Athreya uses a Prospera surveillance protocol for his kidney-pancreas recipients

17:09

How Dr. Hajjiri established Prospera protocols for patients w/ low & high immunological risk

25:37

How Professor Viklicky used Prospera to monitor treatment response in both ABMR and TCMR cases

02:57

Meet Danielle, breast cancer survivor and Signatera patient

01:24

Altera™ Comprehensive Genomic Profiling

01:26

Natera Oncology

39:49

How Dr. Anand’s experience in ProActive Study informed his center’s Prospera surveillance protocol

29:50

How Dr. Batarse diagnosed ABMR despite a negative biopsy from his routine Prospera protocol

06:47

Clinical Validation of a SNP-based Prenatal cfDNA Screening Test for Fetal RHD Status

35:31

Dr. Akkina & Dr. Coleman discuss the continuity of transplant recipient care w/surveillance protocol

03:26

Brent's Inspiring Bladder Cancer Journey | Natera Signatera Test

21:19

Dr. Millie Samaniego bridges the gap between study use & routine care by extending protocolized use

28:39

How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance

16:21

How Dr. Yasir Qazi embraced cell-free DNA surveillance, an unaffected approach due to the CMS update

01:46

Natera Signatera Product Theater at SABCS 2022: The Cycle of ctDNA

01:06

Natera Signatera Product Theater at SABCS 2022: MRD

00:41

Natera Signatera Product Theater SABCS 2022: ctDNA Utility

01:21

Natera Signatera Product Theater at SABCS 2022: Example Case Report - Surveillance

04:01

Natera Signatera Product Theater at SABCS 2022: Exploratory Breast Lead Interval Study (EBLIS)

27:03

Natera Signatera Product Theater at SABCS 2022

03:44

Angela's Story with Signatera

01:03

How ctDNA can enhance patient care

02:01

ctDNA for Patients with Breast Cancer

02:30

Rachelle's Story

02:40

Vista general del tamizaje de portadores de Horizon

02:35

Vista general de la prueba de cáncer hereditario Empower

02:32

Empower Hereditary Cancer Test Overview

02:27

Vistara Single-Gene NIPT Overview

02:35

Vista general de la NIPT de un solo gen Vistara

02:21

Vista general de la prueba de aborto espontáneo Anora

02:39

Horizon Carrier Screening Overview

02:26

Vista general de la NIPT Panorama

02:16

Panorama NIPT Overview

02:18

Learn about SMA and the benefits of carrier screening through Lola’s story

10:38

Lynch Syndrome Short Take - Natera Academy Clinical Education

03:35

“Living with Lynch” - Four Women Share Their Cancer Previvor Journey

09:33

Clinical Review of Lynch Syndrome & Hereditary Cancer

08:58

Jennifer Plent's Story: Lynch Syndrome Cancer Previvor Advises to "Take Control of Your Health"

07:43

Elyse Azriel's Story: "Living with Lynch" - BRCA Testing is Not Enough

01:56

Natera is revolutionizing the standard of care with next-generation, cell-free DNA testing

20:16

Let's Talk about Miscarriage Instagram Live

03:26

Steven's Story: Long-term stable disease on immunotherapy

00:12

Don't believe the myths. You did not cause your miscarriage.

00:15

What is the Anora Miscarriage Test?

02:23

Anora Miscarriage Test Overview

02:31

Patient Perspective: Discovering Genetic Cancer Risk

02:54

Genetic Information Shifts a Breast Cancer Journey: Amy’s Story

02:54

Signatera para el control de la respuesta a la inmunoterapia

00:40

How Does Signatera for Immunotherapy Response Monitoring Work?

02:22

Signatera for immunotherapy response monitoring

03:12

Peace of mind powered by Signatera

01:00:09

World Congress of Melanoma 2021 Breakout Session

02:48

Is the cancer coming back? Using Signatera to detect molecular residual disease (MRD)

03:00

SignaCase: A Case Review: How being informed using Signatera helped Dan through his cancer journey

01:00:31

Breast Cancer Signatera Webinar

04:36

SignaCase: A Case Review: Unexplained Elevated CEA

00:45

Presentando Signatera, una prueba personalizada de sangre con informacion tumoral

18:43

Advances in testing: A personalized, ctDNA assay for MRD detection and surveillance

15:49

ESMO GI Clinical Forum: New customized tools for prediction of risk in CRC